Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Cyclacel Pharma (CYCC) Halted on LUDP
April 4, 2017 10:25 AM EDTCyclacel Pharma (NASDAQ: CYCC) Halted on LUDP
... MoreCyclacel Pharma (CYCC) Continues Monday's Surge Following Preclinical Anti-Cancer Data; Gains Another 40%
April 4, 2017 8:13 AM EDTCyclacel Pharma (NASDAQ: CYCC) adds to Monday's 75% gains after the company announced over the weekend the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor, as a targeted anti-cancer agent.
Shares are up another 40% in pre-open trade to $9.00.
... More
Cyclacel Pharma (CYCC) Surges Following Preclinical Data on CYC065
April 3, 2017 10:09 AM EDTCyclacel Pharma (NASDAQ: CYCC) adds to gains following earlier volatility trading halt and news over the weekend from AACR. Shares are up 54%
Cyclacel Pharma announced the presentation by independent investigators of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK)... More
